Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) <i>BRCA</i> mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy.
Jacob Korach(Tel Aviv University), Éric Pujade-Lauraine(Eau de Paris (France)), Iulian Alecu(AstraZeneca (United Kingdom)), Emma McMurtry(AstraZeneca (United Kingdom)), Ralph Bloomfield(AstraZeneca (United Kingdom)), Tsveta Milenkova(AstraZeneca (United Kingdom)), Simon Turner(Novartis (United States))
Cited by 17
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Certolizumab Pegol for the Treatment of Crohn's Disease
|New England Journal of Medicine|2007|1.1k
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
|New England Journal of Medicine|2007|1.1k